The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases - Scorecard - MDSpire
Advertisement
The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases
Clinical Scorecard: Evaluating Ki67 as a Predictor of Pathological Complete Response and Invasive Disease-Free Survival in HER2-Positive Breast Cancer: A Retrospective Analysis of 244 Cases from Two Centers
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Retrospective analysis conducted at university hospitals in Dresden and Leipzig.
Key Highlights
The study analyzed 244 cases from two centers over an 8-year period, highlighting the need for larger cohorts.
Guideline-Based Recommendations
Diagnosis
Management
Avoid using Ki67 to guide therapeutic decisions due to its lack of predictive value.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Women diagnosed with early HER2-positive breast cancer.
Focus on established predictive factors rather than Ki67 scores.
Clinical Best Practices
Follow the International Ki67 in Breast Cancer Working Group recommendations for Ki67 evaluation.
